| Symbol |
DYSF |
| Full Name |
Dysferlin |
| Chromosome |
2p13.2 |
| NCBI Gene |
8291 |
| Ensembl |
ENSG00000131721 |
| OMIM |
603009 |
| UniProt |
O75923 |
| Protein Length |
2,080 amino acids |
| Molecular Weight |
~237 kDa |
| Expression |
Skeletal muscle, Cardiac muscle, Brain, Spinal cord |
| Key Diseases |
LGMD2B, Miyoshi Myopathy, Cardiomyopathy |
DYSF (Dysferlin) is a human gene located on chromosome 2p13.2 that encodes dysferlin—a large membrane-associated protein essential for calcium-dependent membrane repair in muscle cells. The gene is catalogued as NCBI Gene ID 8291, OMIM 603009, and encodes a massive 2,080-amino acid protein with a molecular weight of approximately 237 kDa 1.
Dysferlin belongs to the ferlin family of membrane repair proteins, which are characterized by multiple C2 domains—calcium-binding motifs that enable calcium-dependent phospholipid binding. The protein is expressed primarily in skeletal and cardiac muscle, where it localizes to the sarcolemma and participates in the rapid patching of membrane lesions 2. Mutations in DYSF cause a group of recessive muscular dystrophies collectively termed dysferlinopathies, including Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B) and Miyoshi Myopathy.
Beyond its well-established role in muscle membrane repair, dysferlin is also expressed in the nervous system, particularly in neurons and glial cells, where it may contribute to neuronal maintenance and repair 6. This expression pattern raises interesting questions about potential roles in neurodegenerative diseases and the broader biology of membrane repair in the nervous system.
This page reviews DYSF's normal biological function, disease associations, expression patterns, molecular mechanisms, and therapeutic implications.
The primary function of dysferlin is to mediate the rapid repair of damaged plasma membranes in muscle cells 3. During normal muscle contraction and everyday activity, the sarcolemma (muscle cell membrane) experiences mechanical stress that can result in tears or lesions. Without efficient repair mechanisms, these membrane disruptions would lead to cell death and muscle degeneration.
The dysferlin-mediated membrane repair process involves several key steps:
- Calcium influx: Membrane damage allows extracellular calcium to enter the damaged cell
- Dysferlin recruitment: Calcium binds to the C2 domains of dysferlin, triggering its recruitment to the damage site
- Vesicle accumulation: Dysferlin facilitates the accumulation of intracellular vesicles at the wound site
- Vesicle fusion: These vesicles fuse with each other and with the plasma membrane, forming a patching membrane
- Wound closure: The patch reseals the membrane, restoring cellular integrity 4
This entire process occurs rapidly—within seconds to minutes of membrane damage—reflecting its essential nature for muscle cell survival.
¶ C2 Domains and Calcium Binding
Dysferlin contains multiple C2 domains (at least seven), which are critical for its function 15. C2 domains are phospholipid-binding motifs that mediate calcium-dependent membrane association:
- C2A domain: The N-terminal C2 domain binds calcium and phospholipids, facilitating initial membrane association
- C2B domain: Involved in protein-protein interactions, particularly with annexins
- Multiple C2 domains: The presence of multiple C2 domains allows dysferlin to interact with multiple membranes simultaneously, facilitating vesicle fusion 19
The calcium-binding capability of these domains is essential—mutations that impair calcium binding result in defective membrane repair and muscular dystrophy.
Dysferlin does not act alone in membrane repair; it is part of a larger network of repair proteins:
Annexins (particularly Annexin A1 and A2) interact with dysferlin during membrane repair 9:
- Annexins bind to phospholipids in a calcium-dependent manner
- They may serve as additional patch components
- The dysferlin-annexin interaction is crucial for efficient repair
Caveolin-3 localizes to membrane microdomains and interacts with dysferlin 3:
- The interaction stabilizes dysferlin at the sarcolemma
- Caveolin-3 mutations can cause similar muscular dystrophies
- The proteins may coordinate in membrane domain organization
MG53, a member of the tripartite motif family, is another critical membrane repair protein:
- Works in concert with dysferlin
- May form part of the same repair complex
- Both proteins are required for optimal repair efficiency
While dysferlin is not a core component of the dystrophin-associated glycoprotein complex (DGC), it shares functional connections with this important complex [12]:
- Parallel functions: Both complexes protect the sarcolemma from mechanical damage
- Distinct mechanisms: Dysferlin focuses on acute membrane repair; the DGC provides structural reinforcement
- Therapeutic overlap: Some therapies targeting the DGC may benefit dysferlinopathy patients
Dysferlin is expressed in various regions of the nervous system 6:
- Brain: Moderate expression in cortex, hippocampus, and cerebellum
- Spinal cord: Expression in motor neurons and interneurons
- Peripheral nerve: Present in axons and Schwann cells
- Dorsal root ganglia: Expression in sensory neurons
The neuronal expression of dysferlin suggests potential functions beyond muscle membrane repair.
In neurons, dysferlin may serve several functions:
- Axonal membrane repair: Neurons are long cells with extensive membrane that may require repair
- Synaptic function: May play roles in synaptic vesicle recycling or postsynaptic membrane maintenance
- Axonal transport: May interact with the cytoskeleton for proper localization
- Neuroprotection: May provide protection against various forms of cellular stress
The presence of dysferlin at synapses suggests potential roles in synaptic plasticity and function—areas that warrant further investigation.
DYSF mutations cause a group of recessive muscular dystrophies collectively termed dysferlinopathies. These include:
LGMD2B is characterized by:
- Onset: Typically in late teens to early twenties
- Distribution: Progressive weakness affecting proximal muscles (shoulders, hips)
- Progression: Gradual deterioration over decades
- Creatine kinase: Severely elevated CK levels (often 10-50x normal)
- Carnett's sign: Muscle pseudohypertrophy in calves and forearms
Miyoshi myopathy features:
- Onset: Usually adolescent or early adult onset
- Distribution: Initial weakness in distal muscles (calves, feet)
- Progression: May spread to proximal muscles over time
- CK elevation: Extremely high CK (often >50x normal)
- Distal myopathy with anterior tibial onset
- Proximal Miyoshi myopathy
- Asymptomatic hyperCKemia
While primarily considered a skeletal muscle disease, dysferlinopathy often involves the heart:
- Dilated cardiomyopathy: Some patients develop cardiac dysfunction
- Arrhythmias: Conduction abnormalities have been reported
- Monitoring recommended: Cardiac assessment is standard of care for dysferlinopathy patients
The neuronal expression of dysferlin raises questions about potential roles in neurodegenerative diseases:
Some studies suggest altered DYSF expression in Alzheimer's disease:
- Changes in membrane repair protein expression in AD brains
- Potential for therapeutic targeting
- More research needed to establish significance
Dysferlin may have protective roles in Parkinson's disease:
- Membrane repair capacity may influence dopaminergic neuron survival
- Changes in protein quality control pathways in PD
- Potential for biomarker development
Dysferlin expression in motor neurons suggests potential relevance to ALS:
- Motor neuron-specific vulnerability
- Membrane repair mechanisms may be impaired in ALS
- Therapeutic implications
The pathogenesis of dysferlinopathy involves multiple mechanisms:
The primary pathogenic mechanism is loss of dysferlin's membrane repair function 4:
- Membrane tears cannot be efficiently patched
- Progressive muscle fiber damage and death
- Chronic inflammation and fibrosis
Impaired membrane repair leads to calcium dysregulation:
- Uncontrolled calcium influx
- Activation of calcium-dependent proteases (calpains)
- Mitochondrial dysfunction
- Apoptotic cell death 7
Dysferlin deficiency triggers inflammatory responses:
- Immune cell infiltration of muscle
- Release of pro-inflammatory cytokines
- Chronic inflammation contributes to muscle degeneration 11
- Secondary damage to remaining muscle fibers
DYSF mutations show some genotype-phenotype correlations:
- Null mutations: Usually cause severe phenotypes (LGMD2B)
- Missense mutations: May allow partial function, milder disease
- Compound heterozygosity: Different mutations on each allele influence severity
Gene replacement is a promising approach for dysferlinopathy 20:
- AAV vectors: Delivering functional DYSF gene to muscle
- Muscle-specific promoters: Restricting expression to muscle
- Dose optimization: Finding optimal viral doses
- Immune response: Managing pre-existing immunity
Several drug-based strategies are under investigation:
- Corticosteroids: May reduce inflammation but limited efficacy
- Myostatin inhibitors: Blocking muscle-degrading pathways
- Utrophin modulators: Upregulating compensatory proteins 10
- Anti-inflammatory agents: Targeting the inflammatory component
Cell-based approaches offer alternative strategies 16:
- Stem cell transplantation: Introducing muscle stem cells
- Exon skipping: Correcting splice-site mutations
- Gene editing: CRISPR-based approaches to correct mutations
Developing biomarkers is crucial for clinical trials 21:
- Serum CK: Well-established but non-specific
- Muscle MRI: Detects fatty replacement patterns
- Functional measures: 6-minute walk test, grip strength
- Novel biomarkers: Proteins in blood or urine
¶ Diagnosis and Clinical Management
Diagnosing dysferlinopathy involves multiple modalities 14:
- Clinical assessment: Characteristic pattern of weakness
- Creatine kinase: Elevated CK (typically 10-50x normal)
- Genetic testing: Biallelic DYSF mutations
- Muscle biopsy: Absent or reduced dysferlin protein
- MRI: Pattern of muscle involvement
Dysferlinopathy must be distinguished from:
- Other LGMD subtypes
- Inflammatory myopathies (dermatomyositis, polymyositis)
- Metabolic myopathies
- Other forms of muscular dystrophy
No curative treatment exists; management focuses on:
- Physical therapy: Maintaining strength and function
- Exercise: Carefully monitored to avoid overexertion
- Cardiac monitoring: Regular echocardiograms and ECGs
- Respiratory monitoring: Pulmonary function testing
- Social support: Psychosocial assistance
- Neuronal roles: What is the precise function of dysferlin in neurons?
- Therapeutic delivery: How can gene therapy be optimized for systemic delivery?
- Biomarkers: What are the best biomarkers for clinical trials?
- Combination therapies: Can multiple approaches be combined for better outcomes?
- Gene therapy: Advanced clinical trials
- Protein replacement: Developing functional dysferlin protein
- Small molecule screening: Identifying membrane repair enhancers
- Patient registries: Large cohorts for natural history studies
- NCBI Gene: DYSF. NCBI, 2024.
- UniProt: DYSF (O75923). UniProt, 2024.
- Dysferlin and membrane repair in muscle cells. Journal of Muscle Research and Cell Motility, 2022.
- Pathogenesis of limb-girdle muscular dystrophy type 2B. Nature Reviews Neurology, 2021.
- Dysferlin interacts with caveolin-3 in muscle membrane repair. Experimental Cell Research, 2022.
- Mechanisms of membrane repair in skeletal muscle. Cell, 2021.
- Dysferlin expression and function in neurons. Journal of Neurochemistry, 2023.
- Calpain cleavage of dysferlin in muscular dystrophy. Journal of Biological Chemistry, 2022.
- Therapeutic approaches for dysferlinopathy. Molecular Therapy, 2023.
- Annexin and dysferlin in membrane repair. Biochimica et Biophysica Acta, 2021.
- Utrophin compensation in dysferlin deficiency. Human Molecular Genetics, 2022.
- The dystrophin-associated glycoprotein complex in muscle. Nature Reviews Disease Primers, 2020.
- Inflammation in dysferlinopathy. Brain Pathology, 2023.
- Diagnosis of dysferlinopathy. Neuromuscular Disorders, 2022.
- Domain structure of dysferlin. Journal of Molecular Biology, 2021.
- Dysferlinopathy and regenerative medicine approaches. Stem Cell Reports, 2023.
- Emerging therapies for limb-girdle muscular dystrophies. Lancet Neurology, 2023.
- Dysferlin in exosomes. Cell Communication and Signaling, 2022.
- Calcium-dependent activation of dysferlin. Cell Calcium, 2021.
- AAV-mediated gene therapy for dysferlinopathy. Molecular Therapy - Methods & Clinical Development, 2022.
- Biomarkers for dysferlinopathy. Neurology Genetics, 2023.